Printer Friendly

IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC

 IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC
 WARREN, N.J., March 19 /PRNewswire/ -- Immunomedics, Inc.


(NASDAQ: IMMU), today reported, at the European Organization for Research and Treatment of Cancer meeting in Amsterdam, the results of a new cancer therapeutic involving loading large numbers of anticancer drugs to tumor-targeting antibodies used by Immunomedics. Immunomedics has licensed this new method of cancer treatment from the Center for Molecular Medicine and Immunology in Newark, N.J., where the preclinical testing of this therapeutic was conducted.
 By the use of spacer molecules, 20-25 molecules of doxorubicin (cancer drug) have been successfully linked to the anticancer antibody that targets carcinoembryonic antigen (CEA), which is present in a wide variety of cancers, including colorectal, breast, lung, pancreatic, ovarian, and cervical. In a series of experiments involving human colorectal cancer growing in mice, it was found that a high retardation of growth of the human colorectal cancer could be achieved without adverse effects in the animals.
 "Doxorubicin is one of the most effective anticancer drugs currently in clinical use, and we hope to further increase its effectiveness by attaching the drug to cancer-targeting antibodies delivering the drug directly to the cancer site," stated Carl Pinsky, vice president, medical affairs. Immunomedics is planning to file an Investigational New Drug (IND) application with the FDA in order to commence Phase I human clinical trials using this new cancer therapeutic.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/19/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY023 -- 9553 03/19/92 09:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:311
Previous Article:LAURA ASHLEY AND FEDERAL EXPRESS BUSINESS LOGISTICS ANNOUNCE GLOBAL ALLIANCE
Next Article:CENTRAL AND SOUTH WEST NAMES DIRECTOR OF MARKETING AND BUSINESS DEVELOPMENT
Topics:


Related Articles
IMMUNOMEDICS ANNOUNCES POSITIVE CLINICAL RESULTS
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR CEA-SCAN IN THE DIAGNOSIS OF MEDULLARY THYROID CANCER
IMMUNOMEDICS' RADIOLABELED ANTIBODY SHOWS ACTIVITY IN OVARIAN CANCER
IMMUNOMEDICS REPORTS PROGRESS WITH CANCER THERAPEUTIC PROGRAM; EIGHT ABSTRACTS PRESENTED AT THE SOCIETY OF NUCLEAR MEDICINE CONFERENCE
IMMUNOMEDICS IS GRANTED TWO U.S. PATENTS
Immunomedics Engages Lehman Brothers As Financial Advisor
Immunomedics, Inc. Reports Second Quarter Results
Immunomedics Patents New Diagnostic and Therapeutic Agents
Immunomedics Reports Progress in Product Commercialization and Cancer Therapeutics at Annual Meeting of Shareholders
Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters